Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.

ABSTRACT: Seasonal allergic rhinitis (SAR) places a significant socioeconomic burden, particularly on individuals with poorly managed recurrent and severe symptoms despite standard-of-care treatment. Stapokibart, a humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha, inhibits its interaction with both IL-4 and IL-13 in type 2 inflammation. Here we aim to assess the efficacy and safety of stapokibart as an add-on therapy in adults with moderate-to-severe SAR. The study was a phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial with 108 patients diagnosed with moderate-to-severe SAR and having baseline blood eosinophil counts ≥300 cells μl^-1. Participants were randomized (1:1) to receive 600 mg (loading dose) to 300 mg stapoki

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC12283386 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature